The Library
Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells
Tools
UNSPECIFIED (2003) Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells. In: 4th International Symposium on Agmatine and Imidazoline Systems, San Diego, CA, APR 09-11, 2003. Published in: AGMATINE AND IMIDAZOLINES: THEIR NOVEL RECEPTORS AND ENZYMES, 1009 pp. 167-174. ISBN 1-57331-498-6. doi:10.1196/annals.1304.019 ISSN 0077-8923.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1196/annals.1304.019
Abstract
The pancreatic beta-cell expresses an imidazoline-binding site that is involved in the regulation of insulin secretion. This site is pharmacologically atypical in comparison with the I-1 and I-2 sites described in other tissues, and it has been classified as I-3. The structural requirements for binding of ligands to the I-3 site have not been fully defined, although a range of synthetic I-3 ligands have been characterized in functional terms. Evidence has been presented that an endogenous I-3 ligand may exist, because extracts of brain contain an active principle that stimulates insulin secretion in a manner consistent with the involvement of I-3 sites. The active component has not been identified but has been equated with the long-sought clonidine displacing substance (CDS) that is proposed as the endogenous ligand for imidazoline-binding sites. Recent evidence has indicated that one active component of CDS may be a beta-carboline, but it is not known whether beta-carbolines can stimulate insulin secretion. Thus, we have studied the effects of beta-carbolines on insulin secretion and cytosolic Ca2+ levels in rodent and human islet cells. The results reveal that harmane, pinoline, and norharmane cause a dose- and glucose-dependent increase in insulin secretion but show that this response differs in a number of ways from that elicited by the well-characterized I-3-agonist, efaroxan. Thus, beta-carbolines represent a new class of insulin secretagogues, although it remains unclear whether their action is mediated solely by I-3 sites in the beta cell.
Item Type: | Conference Item (UNSPECIFIED) | ||||
---|---|---|---|---|---|
Subjects: | Q Science | ||||
Series Name: | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES | ||||
Journal or Publication Title: | AGMATINE AND IMIDAZOLINES: THEIR NOVEL RECEPTORS AND ENZYMES | ||||
Publisher: | NEW YORK ACAD SCIENCES | ||||
ISBN: | 1-57331-498-6 | ||||
ISSN: | 0077-8923 | ||||
Editor: | Piletz, JE and Regunathan, S and Ernsberger, P | ||||
Official Date: | 2003 | ||||
Dates: |
|
||||
Volume: | 1009 | ||||
Number of Pages: | 8 | ||||
Page Range: | pp. 167-174 | ||||
DOI: | 10.1196/annals.1304.019 | ||||
Publication Status: | Published | ||||
Title of Event: | 4th International Symposium on Agmatine and Imidazoline Systems | ||||
Location of Event: | San Diego, CA | ||||
Date(s) of Event: | APR 09-11, 2003 |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |